Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholate for the primary treatment of invasive candidiasis. METHODS: We enrolled patients who had clinical evidence of infection and a positive culture for candida species from blood or another site. Patients were stratified according to the severity of disease, as indicated by the Acute Physiology and Chronic Health Evaluation (APACHE II) score, and the presence or absence of neutropenia and were randomly assigned to receive either caspofungin or amphotericin B. The study was designed to compare the efficacy of caspofungin with that of amphotericin B in patients with invasive candidiasis and in a subgroup with candidemia. RESULTS: Of the 239 patients enrolled, 224 were included in the modified intention-to-treat analysis. Base-line characteristics, including the percentage of patients with neutropenia and the mean APACHE II score, were similar in the two treatment groups. A modified intention-to-treat analysis showed that the efficacy of caspofungin was similar to that of amphotericin B, with successful outcomes in 73.4 percent of the patients treated with caspofungin and in 61.7 percent of those treated with amphotericin B (difference after adjustment for APACHE II score and neutropenic status, 12.7 percentage points; 95.6 percent confidence interval, -0.7 to 26.0). An analysis of patients who met prespecified criteria for evaluation showed that caspofungin was superior, with a favorable response in 80.7 percent of patients, as compared with 64.9 percent of those who received amphotericin B (difference, 15.4 percentage points; 95.6 percent confidence interval, 1.1 to 29.7). Caspofungin was as effective as amphotericin B in patients who had candidemia, with a favorable response in 71.7 percent and 62.8 percent of patients, respectively (difference, 10.0 percentage points; 95.0 percent confidence interval, -4.5 to 24.5). There were significantly fewer drug-related adverse events in the caspofungin group than in the amphotericin B group. CONCLUSIONS: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For invasive candidiasis, echinocandins were a great development that lowered the mortality associated with these infections, with low toxicity and few interactions with other medication (Mora-Duarte et al., 2002; Pappas et al., 2016).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Mora-Duarte et al., 2002
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Nguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C. E., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Self-citationVillanueva, A., Gotuzzo, E., Arathoon, E. G., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J., & Sable, C. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01191-9 · Cited by 292
Self-citation
Research works printed but not linked: 4
- Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis, and treatment. 2nd ed. New York: Raven Press, 1992:279-329.
- Yamamura DL, 1999, CMAJ, 160, 493
- Bachman SP, Pera S, Kirkpatrick WR, Patterson TF, Lopez-Ribot JL. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000. Washington, D.C.: American Society for Microbiology, 2000:352. abstract.
- Nucci M, Santos LM, Ferradosa AS, Colombo AL. Epidemiology of candidemia due to C. parapsilosis in tertiary care hospitals in Brazil. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2001:393. abstract.
Cited by
Items 201–300 of 1,000
Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
Garcia-Effron, G., Chua, D. J., Tomada, J. R., DiPersio, J., Perlin, D. S., Ghannoum, M., & Bonilla, H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00998-09 · Cited by 102
The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia
Sobel, J. D. (2006) · Current Infectious Disease Reports · doi:10.1007/s11908-006-0016-6 · Cited by 127
Candida in Solid Organ Transplant Recipients
Pappas, P. G., & Silveira, F. P. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02909.x · Cited by 111
Vazquez, J., Reboli, A. C., Pappas, P. G., Patterson, T. F., Reinhardt, J., Chin-Hong, P., Tobin, E., Kett, D. H., Biswas, P., & Swanson, R. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-97 · Cited by 101
What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead
Bassetti, M., Righi, E., Montravers, P., & Cornely, O. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx445 · Cited by 98
Fungal Infections of the CNS: Treatment Strategies for the Immunocompromised Patient
Black, K. E., & Baden, L. R. (2007) · CNS Drugs · doi:10.2165/00023210-200721040-00004 · Cited by 115
Treatment of invasive candidiasis in the elderly: a review
Dimοpoulos, G., Flevari, A., Θεοδωρακοπούλου, Μ., VELEGRAKI, & Armaganidis (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s39120 · Cited by 132
Kett, D. H., Shorr, A. F., Reboli, A. C., Reisman, A. L., Biswas, P., & Schlamm, H. T. (2011) · Critical Care · doi:10.1186/cc10514 · Cited by 100
Bhatti, Z., Shaukat, A., Almyroudis, N. G., & Segal, B. H. (2006) · Mycopathologia · doi:10.1007/s11046-006-0025-x · Cited by 111
Gumbo, T., Drusano, G. L., Liu, W., Kulawy, R. W., Fregeau, C., Hsu, V., & Louie, A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01337-06 · Cited by 101
Antifungal agents and liver toxicity: a complex interaction
Tverdek, F. P., Kofteridis, D., & Kontoyiannis, D. P. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1199272 · Cited by 99
Echinocandins — An Advance in the Primary Treatment of Invasive Candidiasis
Walsh, T. J. (2002) · New England Journal of Medicine · doi:10.1056/nejme020142 · Cited by 100
Gauthier, G. M., Nork, T. M., Prince, R., & Andes, D. (2005) · Clinical Infectious Diseases · doi:10.1086/431761 · Cited by 99
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99
“Intrinsic reduced susceptibility has an unclear clinical significance as patients are often successfully treated with echinocandin drugs [36–39], although clinical efficacy may vary with patient population [40–42].”
Potential for Interactions between Caspofungin and Nelfinavir or Rifampin
Stone, J. A., Migoya, E. M., Hickey, L., Winchell, G. A., Deutsch, P. J., Ghosh, K., Freeman, A., Bi, S., Desai, R., Dilzer, S. C., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4306-4314.2004 · Cited by 99
Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis
Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., & Scalise, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00111-06 · Cited by 98
When Primary Antifungal Therapy Fails
Nucci, M., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/587101 · Cited by 99
Self-citationCornely, O. A. (2008) · Infection · doi:10.1007/s15010-008-7357-z · Cited by 112
Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis
Gafter‐Gvili, A., Vidal, L., Goldberg, E., Leibovici, L., & Paul, M. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1011 · Cited by 102
Management of neonatal candidiasis
ROWEN, J. L., & TATE, J. M. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199811000-00008 · Cited by 93
Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches
Tortorano, A. M., Prigitano, A., Morroni, G., Brescini, L., & Barchiesi, F. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s274872 · Cited by 122
Advances in Topical and Systemic Antifungals
Zhang, A. Y., Camp, W. L., & Elewski, B. E. (2007) · Dermatologic Clinics · doi:10.1016/j.det.2007.01.002 · Cited by 108
Weighing the Hazards of Erythropoiesis Stimulation in Patients with Cancer
Khuri, F. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078101 · Cited by 105
Weinberger, M., Leibovici, L., Perez, S., Samra, Z., Ostfeld, I., Levi, I., Bash, E., Turner, D., Goldschmied‐Reouven, A., Regev‐Yochay, G., et al. (2005) · Journal of Hospital Infection · doi:10.1016/j.jhin.2005.02.009 · Cited by 109
Böhme, A., Ruhnke, M., Buchheidt, D., Karthaus, M., Einsele, H., Guth, S., Heussel, G., Heußel, C. P., Junghanß, C., Kern, W. V., et al. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0767-1 · Cited by 104
Strategies to Reduce Mortality in Adult and Neonatal Candidemia in Developing Countries
Kaur, H., & Chakrabarti, A. (2017) · Journal of Fungi · doi:10.3390/jof3030041 · Cited by 93
Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis
Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J. G. T., Würthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M., Franklin, J., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05134-11 · Cited by 93
Sirohi, B., Powles, R. L., Chopra, R., Russell, N. H., Byrne, J., Prentice, H. G., Potter, M. N., & Koblinger, S. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705398 · Cited by 93
Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review
Blyth, C. C., Palasanthiran, P., & O'Brien, T. A. (2007) · PEDIATRICS · doi:10.1542/peds.2006-2931 · Cited by 104
Golan, Y., Wolf, M. P., Pauker, S. G., Wong, J. B., & Hadley, S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-12-200512200-00004 · Cited by 95
Candida Endophthalmitis: Focus on Current and Future Antifungal Treatment Options
Khan, F. A., Slain, D., & Khakoo, R. A. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.12.1711 · Cited by 93
Chhablani, J. K. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.139 · Cited by 95
Barnes, R. A., White, P. L., Bygrave, C., Evans, N., Healy, B., & Kell, J. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.058354 · Cited by 91
Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.7.3117-3119.2004 · Cited by 90
Treatment options of invasive fungal infections in adults
Marchetti, O., Eggimann, P., Pittet, D., Glauser, M., & Calandra, T. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11392 · Cited by 90
Supplement: Trends in invasive Candida infections and their treatment: focus on echinocandins
(2009) · Current Medical Research and Opinion · doi:10.1185/03007990902990817 · Cited by 89
Gastrointestinal infections in immunocompromised hosts
Thom, K. A., & Forrest, G. N. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.mog.0000196149.29077.0d · Cited by 89
Echinocandins in the management of invasive fungal infections, part 1
Morris, M. I., & Villmann, M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050464.p1 · Cited by 86
Espinel‐Ingroff, A., Pfaller, M. A., Messer, S. A., Knapp, C. C., Holliday, N. M., & Killian, S. B. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.2.718-721.2004 · Cited by 94
Caspofungin: first approved agent in a new class of antifungals
Johnson, M. D., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.807 · Cited by 85
“Based upon these findings, the authors conclude that caspofungin is an appropriate and less toxic alternative to amphotericin B for the treatment of invasive candidiasis [13].”
BackgroundResultInfluentialSelf-citationAntifungal stewardship in invasive Candida infections
Ruhnke, M. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12622 · Cited by 99
Echinocandin antifungals: review and update
Morrison, V. A. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.2.325 · Cited by 84
Invasive Candidiasis: An Overview from Taiwan
Ruan, S., & Hsueh, P. (2009) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60091-7 · Cited by 94
Seifert, H., Aurbach, U., Stefanik, D., & Cornely, O. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01217-06 · Cited by 84
Current Options in Antifungal Pharmacotherapy
Mohr, J., Johnson, M., Cooper, T., Lewis, J. S., & Ostrosky‐Zeichner, L. (2008) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.5.614 · Cited by 84
Toward more effective antifungal therapy: the prospects of combination therapy
Kontoyiannis, D. P., & Lewis, R. E. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05007.x · Cited by 85
Sanz-Rodrı́guez, C., López‐Duarte, M., Jurado, M., Lopez, J., Arranz, R., Cisneros, J. M., Martino, M. L., García-Sánchez, P., Morales, P., Olivé, T., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704516 · Cited by 84
Slenker, A. K., Keith, S. W., & Horn, D. L. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.02.004 · Cited by 91
Ullmann, A. J. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001884 · Cited by 84
Advances in Antifungal Therapy
Sable, C. A., Strohmaier, K. M., & Chodakewitz, J. A. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.062906.071602 · Cited by 81
Self-citationCaspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients
Senn, L., Eggimann, P., Ksontini, R., Pascual, A., Demartines, N., Billé, J., Calandra, T., & Marchetti, O. (2009) · Intensive Care Medicine · doi:10.1007/s00134-009-1405-8 · Cited by 100
Management of Invasive Candidiasis in Critically Ill Patients
Blot, S. I., & Vandewoude, K. (2004) · Drugs · doi:10.2165/00003495-200464190-00002 · Cited by 84
Fungal infections in solid organ transplantation
Marik, P. E. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.3.297 · Cited by 82
Invasive fungal infections in patients with cancer in the Intensive Care Unit
Sipsas, N. V., & Kontoyiannis, D. P. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.11.017 · Cited by 81
Chen, S. C., Sorrell, T. C., Chang, C. C., Paige, E. K., Bryant, P. A., & Slavin, M. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12597 · Cited by 88
Invasive Fungal Infections in the Intensive Care Unit
Ostrosky-Zeichner, L., & Al-Obaidi, M. (2017) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2017.05.005 · Cited by 76
Ruhnke, M., Cornely, O. A., Schmidt‐Hieber, M., Alakel, N., Boell, B., Buchheidt, D., Christopeit, M., Hasenkamp, J., Heinz, W., Hentrich, M., et al. (2020) · Mycoses · doi:10.1111/myc.13082 · Cited by 88
Lye, D. C. B., Hughes, A., O'Brien, D., & Athan, E. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0038-2 · Cited by 75
Candidemia and invasive candidiasis: A review of the literature for the burns surgeon
Ha, J. F., Italiano, C. M., Heath, C. H., Shih, S., Rea, S. M., & Wood, F. M. (2010) · Burns · doi:10.1016/j.burns.2010.01.005 · Cited by 97
Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers
Neely, M., Jafri, H. S., Seibel, N., Knapp, K., Adamson, P. C., Bradshaw, S. K., Strohmaier, K. M., Sun, P., Bi, S., Dockendorf, M. F., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01027-08 · Cited by 79
Self-citationGuidelines for Antibiotic Prescription in Intensive Care Unit
Guleria, R., Mohan, A., Kulkarni, A. P., Madan, K., & Hadda, V. (2019) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23101 · Cited by 94
Clinical perspectives on echinocandin resistance among Candida species
Shields, R. K., Nguyen, M. H., & Clancy, C. J. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000215 · Cited by 76
Betts, R., Glasmacher, A., Maertens, J., Maschmeyer, G., Vazquez, J. A., Teppler, H., Taylor, A., Lupinacci, R., Sable, C., & Kartsonis, N. (2006) · Cancer · doi:10.1002/cncr.21615 · Cited by 75
Self-citationKeating, G. M., & Figgitt, D. P. (2003) · Drugs · doi:10.2165/00003495-200363200-00008 · Cited by 83
Chau, M., Daveson, K., Alffenaar, J. C., Gwee, A., Ho, S. A., Marriott, D. J. E., Trubiano, J. A., Zhao, J., & Roberts, J. A. (2021) · Internal Medicine Journal · doi:10.1111/imj.15587 · Cited by 78
Mai, H., Champion, L., Ouali, N., Hertig, A., Péraldi, M., Glotz, D., Rondeau, É., Costa, M.-A., Snanoudj, R., Benoît, G., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000239188.27153.23 · Cited by 75
Wiederhold, N. P., Najvar, L. K., Bocanegra, R., Molina, D., Olivo, M., & Graybill, J. R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00105-07 · Cited by 75
Clancy, C. J., Huang, H., Cheng, S., Derendorf, H., & Nguyen, M. H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-06 · Cited by 73
Aguado, J. M., Ruíz-Camps, I., Muñóz, P., Mensa, J., Almirante, B., Vázquez, L., Rovira, M., Martín‐Dávila, P., Moreno, A., Álvarez-Lerma, F., et al. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2011.01.008 · Cited by 94
Gorschlüter, M., Mey, U., Strehl, J., Schmitz, V., Rabe, C., Pauls, K., Ziske, C. G., Schmidt‐Wolf, I. G. H., & Glasmacher, A. G. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-35 · Cited by 84
Moellering, R. C., Graybill, J. R., McGowan, J. E., & Corey, L. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.04.001 · Cited by 84
Modes of the antibiotic activity of amphotericin B against Candida albicans
Grela, E., Zdybicka‐Barabas, A., Pawlikowska-Pawlęga, B., Cytryńska, M., Włodarczyk, M., Grudziński, W., Luchowski, R., & Gruszecki, W. I. (2019) · Scientific Reports · doi:10.1038/s41598-019-53517-3 · Cited by 86
European expert opinion on the management of invasive candidiasis in adults
Kullberg, B. J., Verweij, P. E., Akova, M., Arendrup, M. C., Billé, J., Calandra, T., Cuenca‐Estrella, M., Herbrecht, R., Jacobs, F., Kalin, M., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03615.x · Cited by 78
Kohno, S., Izumikawa, K., Yoshida, M., Takesue, Y., Oka, S., Kamei, K., Miyazaki, Y., Yoshinari, T., Kartsonis, N. A., & Niki, Y. (2013) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1754-z · Cited by 73
Self-citationSignificant differences in drug susceptibility among species in the Candida parapsilosis group
Asbeck, E. C. V., Clemons, K. V., Martinez, M., Tong, A.-J., & Stevens, D. A. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.04.019 · Cited by 79
Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients
Herbrecht, R., Flückiger, U. M., Gachot, B., Ribaud, P., Thiébaut, A., & Cordonnier, C. (2007) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2007.06.007 · Cited by 73
Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey
Groll, A. H., Attarbaschi, A., Schuster, F. R., Herzog, N., Grigull, L., Dworzak, M. N., Beutel, K., Laws, H., & Lehrnbecher, T. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl009 · Cited by 75
Overview of treatment options for invasive fungal infections
Pound, M. W., Townsend, M. L., Dimondi, V., Wilson, D., & Drew, R. H. (2011) · Medical Mycology · doi:10.3109/13693786.2011.560197 · Cited by 70
Antifungal prophylaxis in pediatric hematology/oncology: New choices & new data
Dvorak, C. C., Fisher, B. T., Sung, L., Steinbach, W. J., Nieder, M. L., Alexander, S. W., & Zaoutis, T. E. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23415 · Cited by 71
Management bundles for candidaemia: the impact of compliance on clinical outcomes
Takesue, Y., Ueda, T., Mikamo, H., Oda, S., Takakura, S., Kitagawa, Y., KOHNO, S., on behalf of the ACTIONs Project, Masuda, A., Yoshida, C., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku414 · Cited by 77
Echinocandin pharmacodynamics: review and clinical implications
Pound, M. W., Townsend, M. L., & Drew, R. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq081 · Cited by 67
Liposomal amphotericin B: what is its role in 2008?
Lanternier, F., & Lortholary, O. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01984.x · Cited by 78
Recombinant antibodies: a natural partner in combinatorial antifungal therapy
Matthews, R., & Burnie, J. (2003) · Vaccine · doi:10.1016/j.vaccine.2003.11.032 · Cited by 70
Mazi, P. B., Olsen, M. A., Stwalley, D., Rauseo, A. M., Ayres, C., Powderly, W. G., & Spec, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac004 · Cited by 68
Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults
Bow, E. J., Evans, G., Fuller, J., Laverdière, M., Rotstein, C., Rennie, R., Shafran, S. D., Sheppard, D., Carle, S., Phillips, P., et al. (2010) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2010/357076 · Cited by 70
Self-citationNovel strategies to fightCandidaspecies infection
Rodrigues, M. E., Silva, S. M., Azeredo, J., & Henriques, M. (2014) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2014.974500 · Cited by 78
Antifungals to treatCandida albicans
Moudgal, V. V., & Sobel, J. D. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.493875 · Cited by 85
Management of candidiasis in the intensive care unit
Schelenz, S. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm430 · Cited by 69
Candida glabrata Endophthalmitis Treated Successfully with Caspofungin
Sarria, J. C., Bradley, J. C., Habash, R., Mitchell, K. T., Kimbrough, R. C., & Vidal, A. M. (2005) · Clinical Infectious Diseases · doi:10.1086/427753 · Cited by 68
Pfaller, M. A., Chaturvedi, V., Diekema, D. J., Ghannoum, M. A., Holliday, N. M., Killian, S. B., Knapp, C. C., Messer, S. A., Miskov, A., & Ramani, R. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00493-08 · Cited by 68
Issues in antifungal susceptibility testing
Johnson, E. M. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm427 · Cited by 70
Lamoth, F., Lewis, R. E., & Kontoyiannis, D. P. (2020) · Journal of Fungi · doi:10.3390/jof7010017 · Cited by 69
Candoni, A., Mestroni, R., Damiani, D., Tiribelli, M., Michelutti, A., Silvestri, F., Castelli, M., Viale, P., & Fanin, R. (2005) · European Journal of Haematology · doi:10.1111/j.1600-0609.2005.00500.x · Cited by 67
Sun, H., & Singh, N. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.020 · Cited by 74
Recommendations for the treatment of established fungal infections
Thursky, K., Playford, E. G., Seymour, J. F., Sorrell, T. C., Ellis, D. H., Guy, S., Gilroy, N. M., Chu, J., & Shaw, D. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01725.x · Cited by 68
Muñóz, P., Singh, N., & Bouza, E. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000235164.70678.97 · Cited by 67
Candidemia in the Intensive Care Unit
Epelbaum, O., & Chasan, R. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.04.010 · Cited by 78
Clinical efficacy of new antifungal agents
Kauffman, C. A. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.08.001 · Cited by 64
Garnacho-Montero, J., Díaz-Martín, A., Cantón-Bulnes, L., Ramírez, P., Sierra, R., Arias-Verdú, D., Rodríguez-Delgado, M., Loza-Vázquez, A., Rodriguez-Gomez, J., Gordón, M., et al. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000002867 · Cited by 62
Michallet, M., & Ito, J. I. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1178 · Cited by 69
Metadata
- Authors
- Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J.
- Affiliations
- Costa Rican Department of Social Security (CR)
- University of Rochester (US)
- McMaster University (CA)
- Universidade Federal de São Paulo (BR)
- Clinica Santa Maria (CL)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-12-19
- Volume
- 347
- Issue
- 25
- Pages
- 2020-2029
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003661565
- Cited by
- 1,380
- References
- 31
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 17 · 2023: 14 · 2022: 18 · 2021: 30 · 2020: 28 · 2019: 30 · 2018: 29 · 2017: 44 · 2016: 30 · 2015: 50 · 2014: 44 · 2013: 53 · 2012: 62
- FWCI
- 56.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, amphotericin B deoxycholate, invasive candidiasis, candidemia, echinocandins, antifungal therapy, treatment efficacy, drug-related adverse events, neutropenia, APACHE II score, Candida species, randomized trial comparison, length of hospital stay, cost-effectiveness
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candida, Candidiasis, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Peptides, Peptides, Cyclic, Recurrence, Fungemia, APACHE, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.